HPV Testing In Polish POpulation-based Cervical Cancer Screening Program.

Cervical Cancer Clinical Trial

— HIPPOPROJECT  

Official title:

HPV Testing In Polish POpulation-based Cervical Cancer Screening Program - a Randomized Healthcare Policy Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04111835
• Other study ID #: 28/2019
• Secondary ID: 28/2019/1/2020
• Status: Completed
• Phase: N/A
• Start date: October 28, 2019
• Est. completion date: December 31, 2023

Study information

• Verified date: January 2024
• Source: Maria Sklodowska-Curie National Research Institute of Oncology
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The HIPPO PROJECT is a randomized healthcare study nested in the OCCSP in Poland. This project will assess the performance of the new screening test (HR HPV test) before its implementation in Poland.

Description:

The study assumes randomized assumption of 33,000 women aged 30-59 to cytology or HR HPV test in a 1:1 ratio with age stratification (three strata: 30-39, 40-49 and 50-59 years).

Patients are recruited by the Cervical Cancer Prevention Clinic at the Department of Cancer Prevention at the Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw (main centre) and 8 more sites from distant regions of Poland (Lublin, Masovian, Silesian, Swietokrzyskie and West Pomeranian Voivodeship). All sites are selected through a tendering process and have to fulfil several criteria for inclusion into the project (active participation in the OCCSP, being certified for HPV testing with the chosen clinically validated hrHPV DNA assays)to obtain results representative for the entire country.

Gynaecological clinics:

Lublin Voivodeship:

• Non-Public Health Care Department MED -SPEC in Zamosc

• Plus Clinic in Zamosc

• Medical Center - Diagnostic in Lukow

Masovian Voivodeship:

• Medical Center - Diagnostic Siedlce, Kleeberg Street 2 Minsk Mazowiecki, Dąbrówki Street 2 Lukow, Krynka Street 1C Nur, Drohiczyńska Street 8, Sterdyn, Lipowa Street 1A, 08-320 Sterdyn Zelechow, Piłsudskiego Street 34 Strachowka, Norwida Street 6A Wierzbno, Wierzbno Street 88 Latowicz, Nowowiejska Street 34, Wielgolas

• Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw

• St. John Paul II Mazovian Provincial Hospital in Siedlce

Silesian Voivodeship:

• Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw on Gliwice

• SUPRA-MED in Bielsko-Biała

• SUPRA-MED in Wilkowice

• Gynecology and Obstetrics Clinic "K na Żeromskiego" in Wodzisław Slaski

• Medical Center in Rybnik

• Non-public Health Care JARO in Wodzisław Slaski

• Non-public Health Care EVA in Lubliniec

• SIKORNIK Clinic in Gliwice

Swietokrzyskie Voivodeship:

• Holy Cross Cancer Centre in Kielce

West Pomeranian Voivodeship:

• Non-public Health Care MULTIMED Gynecology and Obstetrics in Koszalin Koszalin, Monte Casino Street 13 Koszalin, Sw. Wojciecha Street 1 Koszalin, Kolejowa Street 71 Koszalin, Lelewela Street7 Bedzino Street 18

• "Hospital in Szczecinek"

Cytological&molecular laboratories

• Maria Sklodowska-Curie National Research Institute of Oncology; Roentgen Street 5, Warsaw, Armii Krajowej Street 15, 44-102 Gliwice (branch in Gliwice),

• Holy Cross Cancer Centre; Prezydent Stefan Artwinski Street 3, 25-734 Kielce,

• Medical Center - Diagnostic; Niklowa Street 9, 08-110 Siedlce,

• ALAB Laboratories; Stępinska Street 22/30, 00-739 Warsaw,

• Non-public Health Care Center MEDITEST Medical Diagnostics; Bronislawy Street 14D, 70-533 Szczecin,

• Non-public Health Care MULTIMED Gynecology and Obstetrics; Monte Casino Street 13, 75-414 Koszalin,

• Non-Public Health Care Department of Pathomorphology ALFAMED. Edward Cwierz, Maciej Cwierz; Jana Kilinskiego Street 78, 22a-400 Zamosc,

• Femina. Medical Centre; Klodnicka Street 23, 40-703 Katowice.

Colposcopy clinics

• Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw

• Non-public Health Care Center MEDITEST Medical Diagnostics in Szczecin

• Maria Sklodowska-Curie National Research Institute of Oncology in Gliwice

• Non-public Health Care MULTIMED Gynecology and Obstetrics

• St. John Paul II Mazovian Provincial Hospital in Siedlce

• Femina. Medical Centre in Katowice

• Holy Cross Cancer Centre in Kielce

• Medical Center - Diagnostic in Siedlce

• Non-Public Health Care Department of Pathomorphology ALFAMED. Edward Cwierz, Maciej Cwierz in Zamosc

The primary endpoint is the detection rate (DR) of histologically confirmed CIN2 or higher in each screening arm and detection rate ratio (DRR) of CIN2+ in HPV test vs cytology arm in intention-to-treat (ITT) analysis. Secondary endpoints include detection rate ratio of CIN1+, CIN3+ (including adenocarcinoma in situ) and invasive CC in both ITT and per-protocol (PP) analysis, restricted to women who adhered to the foreseen follow-up.

Other outcome measures are: (1) distribution of women by the screening test results; (2) referral rate for colposcopy; (3) compliance with referral for colposcopy; (4) positive predictive value of referral for colposcopy calculated for each screening test and separately by histology results (no CIN, CIN1, CIN2, CIN3, AIS, CIN2+, CIN3+, invasive cancer (squamous/adenocarcinoma)); (5) DR of histologically confirmed CIN2+ in patients with hrHPV positive test, two NILM LBCs six months apart and a positive CINtePlus Cytology and/or Qiasure test; (6) DRR of histologically confirmed CIN2+ after CINtec® PLUS Cytology test vs. QIASURE methylation test; (7) yield of use of CINtec® PLUS Cytology test vs. QIASURE methylation test in terms of detection rate of histologically confirmed CIN2+.

Additionally, biobanking of cytological samples taken from patients participating in the HIPPO Project is planned in Maria Sklodowska-Curie National Research Institute of Oncology for the purpose of potential future restrospective analyses if new cervical cancer screening technologies emerge.

The study was approved by the Bioethics Committee of National Research Institute of Oncology (ID: 28/2019/1/2020).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 33000
• Est. completion date: December 31, 2023
• Est. primary completion date: November 3, 2022
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 30 Years to 59 Years

Eligibility

Inclusion Criteria:

-women aged 30-59 with no screening Pap test within the preceding three years in the OCCSP and women with risk factors entitled to annual screening based on information from the SIMP and not tested within preceding 12 months (based on information from the screening database SIMP)

Exclusion Criteria:

-women with screening Pap test within the preceding three years in the OCCSP

Related Conditions & MeSH terms

• Cervical Cancer
• Uterine Cervical Neoplasms

Intervention

Diagnostic Test:
• Offering an alternative cervical cancer screening method - hrHPV molecular testing.
Women randomized to this screening strategy group will take a hrHPV molecular test. hrHPV-positive - reflex LBC: Abnormal reflex LBC (ASC-US or worse) -> colposcopy Normal reflex LBC -> repeat LBC in 6 months Positive - colposcopy Negative - rescreen in 3 years HPV-negative - rescreen in 5 years

Locations

Country	Name	City	State
Poland	Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw	Warsaw

Sponsors (2)

Lead Sponsor	Collaborator
Maria Sklodowska-Curie National Research Institute of Oncology	Ministry of Health, Poland

Country where clinical trial is conducted

Poland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Distribution of women by the screening test results	This is for conventional cytology and LBC - according the modified Bethesda 2014 system used in the program. We will analyze the number of women due to the result of screening test in each arm.	12 months after the date of the positive screening test
Other	Referral rate for colposcopy for each screening test	Analyses will be performed on data collected in SIMP. We will check the compliance on referral for colposcopy for each screening.	12 months after the date of the positive screening test
Other	Positive predictive value of referral for colposcopy calculated for each screening test and separately	Histology: No CIN, CIN1, CIN2, CIN3, AIS, CIN2+, CIN3+, invasive cancer (squamous/adenocarcinoma).	12 months after the date of the positive screening test
Other	Detection rates of histologically confirmed CIN2+ in patients with second negative LBC result	Detection rates of histologically confirmed CIN2+ in patients with second negative LBC result: after CINtec PLUS Cytology test and after QIASURE methylation test; detection rate ratio of histologically confirmed CIN2+ after CINTEC test vs after QIASURE methylation test	12 months after the date of the positive screening test
Other	Yield of use of additional diagnostic tests in terms of detection rate of histologically confirmed CIN2+	Number of women with histologically confirmed CIN2+ after CINtec test/number of women screened with HPV test	12 months after the date of the positive screening test
Other	Yield of use of additional diagnostic tests in terms of detection rate of histologically	Number of women with histologically confirmed CIN2+ after QIASURE methylation test/number of women screened with HPV test	12 months after the date of the positive screening test
Primary	Detection rate of histologically confirmed CIN2 or worse in each screening arm		12 months after the date of the positive screening test
Primary	Detection rate ratio of CIN2+ in HPV test vs cytology arm (and detection rate ratios between the hrHPV test and cytology)	This is defined as: number of women with CIN2+ detected in the HPV arm/women screened by HPV; ...........................................................................................................................; number of women with CIN2+ detected in the cytology arm/women screened in with cytology	12 months after the date of the positive screening test
Secondary	Detection rate ratio of CIN1+, CIN3+ (including adeno-carcinoma-in-situ) and cervical cancer (ITT).		12 months after the date of the positive screening test
Secondary	Detection rate ratios of CIN2+ (and CIN1+, CIN3+, cancer) in the per-protocol analysis, restricted to women who adhered to the foreseen follow-up.		12 months after the date of the positive screening test